Clinical Trials for MELAS Syndrome: Current Research and Treatment Studies
MELAS syndrome is a rare genetic disorder affecting cellular energy production, causing muscle weakness, stroke-like episodes, and neurological problems. Currently, 4 clinical trials are investigating new treatments for this condition across several European countries. These trials are testing experimental medications including TTI-0102, zagociguat, and nipocalimab, aiming to improve symptoms such as fatigue, cognitive function, and overall quality of life for patients. (Also known as: Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes)
Clinical trial locations
- Czechia
- France
- Germany
- Study on the Safety and Effectiveness of Zagociguat for Treating MELAS in Patients
- Long-term safety study of zagociguat tablets in patients with MELAS syndrome (Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) who completed previous trial
- Study on Nipocalimab for Adults with Active Inflammatory Muscle Diseases
- Hungary
- Italy
- Study on the Safety and Effectiveness of Zagociguat for Treating MELAS in Patients
- Long-term safety study of zagociguat tablets in patients with MELAS syndrome (Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) who completed previous trial
- Study on Nipocalimab for Adults with Active Inflammatory Muscle Diseases
- Netherlands
- Poland
- Spain
Study on the Effects of TTI-0102 for Patients with MELAS Syndrome
This trial is investigating TTI-0102, an oral medication derived from an existing drug called Cystagon. The study aims to evaluate whether TTI-0102 can safely and effectively improve symptoms in people living with MELAS syndrome.
Who can participate: To join this study, participants must be between 16 and 60 years old with a confirmed diagnosis of MELAS, including the presence of specific genetic mutations. They should have moderate disease severity with a score between 15 and 45 on the Newcastle Mitochondrial Disease Adult Scale. Participants need to be able to walk at least 150 meters but no more than 1,000 meters in a 12-minute walk test. Both men and women must agree to use effective birth control methods throughout the study. If taking dietary supplements such as creatine, CoQ10, or B vitamins, participants must have been on stable doses for at least 3 months and continue them during the trial.
Who cannot participate: The trial excludes people with other serious health conditions that could interfere with the study, those currently in another clinical trial, or anyone planning surgery during the study period. Pregnant or breastfeeding women cannot participate, nor can those with a history of allergic reactions to the study medication. People unable to follow study procedures, take oral medication as directed, or those with substance abuse history or mental health conditions affecting participation are also excluded.
Main focus: The trial evaluates how well TTI-0102 improves walking ability over 12 minutes, quality of life, and fatigue levels. Researchers will also monitor how the body processes the medication by measuring blood levels of certain substances. The study lasts up to six months with regular check-ups at weeks 4, 8, 12, 16, 20, and 24.
Investigational drug: TTI-0102 is an experimental oral medication targeting the energy-producing parts of cells affected in MELAS syndrome.
Study on the Safety and Effectiveness of Zagociguat for Treating MELAS in Patients
This clinical trial tests zagociguat, a tablet medication aimed at improving fatigue and cognitive function in people with MELAS. The study uses a crossover design where participants receive both the active drug and a placebo at different times, allowing researchers to compare the effects.
Who can participate: Adults between 18 and 75 years old with a confirmed MELAS diagnosis can join. They must have documented genetic variants and a history of stroke-like episodes with specific MRI findings. Participants need to be able to complete cognitive tests and score below average on at least one during screening, while also reporting fatigue related to MELAS. They must be able to walk with or without assistance and complete at least one sit-to-stand movement in 30 seconds. A platelet count of at least 150,000 per microliter is required, along with stable Vitamin D levels or supplementation. Both men and women must agree to use highly effective birth control methods from consent through 90 days after the last dose.
Who cannot participate: People outside the age range of 18-75 years, those unwilling to follow study procedures, or anyone with medical conditions or taking medications that might interfere with the trial are excluded. Pregnant or breastfeeding women cannot participate, nor can those who recently joined another clinical trial, have a history of drug or alcohol abuse, or known allergies to the study medication.
Main focus: The 12-week study evaluates whether zagociguat can reduce fatigue and improve thinking abilities using tests like the Groton Maze Learning Test and International Digit Symbol Substitution Test. Safety monitoring includes tracking any unwanted effects throughout the trial.
Investigational drug: Zagociguat is available in 15 mg or 7.5 mg tablet form and works by enhancing cellular energy production pathways.
Long-term safety study of zagociguat tablets in patients with MELAS syndrome who completed previous trial
This is an open-label extension study where all participants receive zagociguat tablets for approximately 3 years. It’s designed for people who completed a previous zagociguat study and aims to evaluate the medication’s long-term safety and tolerability.
Who can participate: Participants must have completed the previous TIS6463-203 trial through Week 12. Women must be either post-menopausal for at least one year, surgically sterile, or if of childbearing potential, have negative pregnancy tests. Both men and women who can have children must use highly effective birth control methods such as hormonal contraception, IUD, or permanent sterilization. Male participants cannot donate sperm from screening through 90 days after the last dose, and female participants cannot donate eggs through 30 days after the final dose.
Who cannot participate: People under 18 or over 65 years old cannot join. The trial excludes pregnant or breastfeeding women, those with severe allergic reactions to medications, anyone currently in other clinical trials, and people with significant kidney or liver problems. Those with uncontrolled high blood pressure, recent stroke or heart attack within six months, active cancer, or severe mental health conditions affecting their ability to follow procedures are also excluded. History of non-compliance with medical treatments and unstable medical conditions are additional exclusion factors.
Main focus: The study monitors long-term safety through regular vital sign checks, ECG tests, laboratory tests, and bone density measurements using DEXA scans. Researchers track kidney function, heart-related proteins, and medication levels in the blood throughout the 156-week period running from September 2025 to August 2027.
Investigational drug: Zagociguat 15 mg tablets taken daily by mouth for the duration of the study.
Study on Nipocalimab for Adults with Active Inflammatory Muscle Diseases
This trial investigates nipocalimab, a solution given through intravenous infusion, for treating active Idiopathic Inflammatory Myopathies. While this study focuses on inflammatory muscle diseases in general, it may include some participants with conditions related to MELAS syndrome.
Who can participate: Participants must have active Idiopathic Inflammatory Myopathies meeting 2017 diagnostic criteria for at least 6 weeks before starting treatment. They need to have specific antibodies related to muscle inflammation detected in blood tests. If using low-strength topical treatments for skin lesions, doses must remain stable for at least 4 weeks before starting and continue unchanged until Week 52. Both men and women are eligible, including vulnerable populations who may need extra care.
Who cannot participate: People with other serious health conditions that could interfere with the study cannot participate. The trial excludes pregnant or breastfeeding women, those with severe allergic reactions to medications, anyone using certain medications affecting study results, those with recent infections requiring treatment, or people with drug or alcohol abuse history. Participation in another recent clinical trial, conditions affecting the immune system, history of cancer except certain skin cancers, and blood disorders are also exclusion criteria.
Main focus: The 52-week study aims to achieve at least minimal improvement in symptoms while reducing the use of oral prednisone. Regular monitoring evaluates treatment effectiveness and safety, with completion expected by March 2027.
Investigational drug: Nipocalimab is a monoclonal antibody administered intravenously that targets specific proteins involved in the immune response to reduce inflammation.
Summary
The four ongoing clinical trials for MELAS syndrome reflect a growing research focus on this rare genetic disorder affecting cellular energy production. Three of the four trials specifically target MELAS, while one broader study on inflammatory muscle diseases may include related conditions.
Geographically, Germany and Italy stand out with participation in three trials each, making them key research centers for MELAS treatment development. France, the Netherlands, and several Central and Eastern European countries also host these studies, indicating a strong European research network.
Two distinct drug candidates dominate the research landscape: TTI-0102, being tested in France and the Netherlands, and zagociguat, with two separate trials in Germany and Italy—one evaluating initial safety and effectiveness, and another providing long-term safety data for patients who completed earlier studies. The zagociguat program demonstrates a comprehensive approach to drug development, following participants over several years.
All trials emphasize safety monitoring alongside effectiveness, recognizing the complex nature of this condition. They focus on improving practical outcomes such as walking ability, fatigue reduction, and cognitive function—aspects that directly impact patients’ daily lives. The age ranges vary considerably, with some studies accepting participants as young as 16 and others limiting enrollment to those under 75, reflecting different approaches to studying this condition across the lifespan.
For patients interested in participating, these trials offer access to experimental treatments while contributing to scientific understanding of MELAS syndrome. However, all trials have specific eligibility requirements regarding disease severity, genetic confirmation, and general health status that must be carefully reviewed with healthcare providers.
